MedPath

FIGO 2018 stage IB2 (>2cm - <=4 cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F)

Phase 2
Recruiting
Conditions
cervical cancer
cervical carcinoma
10038594
Registration Number
NL-OMON54356
Lead Sponsor
Princess Margaret Cancer Centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

Patients must have histologically confirmed invasive cervical cancer with
adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 measuring
>2 cm - <=4 cm

Patients must be >=18 years of age, and < 40 years of age

Patients must be premenopausal and wish to preserve fertility

no prior therapy to treat their cancer lesion, patients with diagnostic cone or
LEEP are allowed but a measurable tumor of >2 cm - <=4 cm is mandatory

Eastern Cooperative Group (ECOG) performance status <= 2

Within 7 days of the proposed start of treatment, patients must have normal
organ and marrow function

No evidence of active uncontrolled infection

Patient must have disease that is measurable per RECIST 1.1.

Ability to understand and willing to sign a written informed consent document.

A negative serum pregnancy test

Exclusion Criteria

Patients who are receiving any other investigational agents.

Patients with other cancers requiring ongoing treatment.

Patients with known / evidence of brain metastases

Uncontrolled inter-current illness

Patients who are pregnant or breastfeeding

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>to determine the rate of functional uterus defined as successful fertility<br /><br>sparing surgery (FSS) with no adjuvant therapy</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>response rate based on RECIST 1.1 following neoadjuvant chemotherapy<br /><br>safety of the fertility sparing surgery (FSS)<br /><br>overall survival (OS) </p><br>
© Copyright 2025. All Rights Reserved by MedPath